Schimmack S, Svejda B, Lawrence B, et al. The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors.Langenbecks Arch Surg 2011; 396(3): 273–298.
O’Toole D, Grossman A, Gross D, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors:biochemical markers. Neuroendocrinology 2009; 90(2): 194–202.
Modlin IM, Gustafsson BI, Moss SF, et al. Chromogranin A – biological function and clinical utility in neuroendocrine tumor disease. Ann Surg Oncol 2010; 17(9): 2427.
Braga F, Ferraro S, Mozzi R, et al. Biological variation of neuroendocrine tumor markers chromogranin A and neuron-specific enolase. Clin Biochem 2013; 46(1–2): 148–151.
Eriksson B, Kloppel G, Krenning E, et al. Consensus Guidelines for the management of patients with digestive neuroendocrine tumors – well differentiated jejunal-ileal tumor/carcinoma. Neuroendocrinology 2008; 87(1): 8–19.
Pape UF, Perren A, Niederle B, et al. ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology 2012; 95(2): 135–156.
Pepe UF, Berndt U, Muller-Nordhorn J, et al. Prognostic factors of long term outcome in gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer 2008; 15(4): 1083–1097.
Bolanowski M, Bednarczuk T, Bobek-Billewicz B, et al. Neuroendocrine neoplasms of the small intestine and the appendix – management guidelines (recommended by the Polish Network of Neuroendocrine Tumors). Endokrynol Pol 2013;64(6): 459–479.
Pavel M, Baudin E, Couvelard A, et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2012; 95(2): 157–176.
Plöckinger U, Wiedenmann B, de Herder WW . ENETS Consensus Guidelines for the standard of care in neuroendocrine tumors.Neuroendocrinology 2009; 90(2): 159–161.
Ducceschi M, Pusceddu S, Platania M. False positives and false negatives in neuroendocrine tumors diagnosis: clinical reports.Tumori 2010; 96(5): 827–832.
de Herder WW . Biochemistry of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007; 21(1): 33–41.
Kos-Kudła B, Blicharz-Dorniak J, Handkiewicz-Junak D, et al. Consensus Conference. Diagnostic and therapeutic guidelines or gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the Polish Network of Neuroendocrine Tumours).Endokrynol Pol 2013; 64(6): 418–443.
Telega A, Kos-Kudła B, Foltyn W, et al. Selected neuroendocrine tumour markers, growth factors and their receptors in typical and atypical bronchopulmonary carcinoids. Endokrynol Pol 2012; 63(6): 477–482.
Kanakis G, Kaltsas G. Biochemical markers for gastroenteropancreatic neuroendocrine tumours (GE P-NET s). Best Pract Res Clin Gastroenterol 2012; 26(6): 791–802.
Kaczmarska-Turek D, Jańczyk A, Witkowska M, i wsp. 58-letni mężczyzna z bólem brzucha i biegunką. W: Bednarczuk T, red.Endokrynologia w przypadkach klinicznych. Kraków: Medycyna Praktyczna; 2014: 60–66.
Rinke A, Müller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PRO MID Study Group. J Clin Oncol 2009; 27(28): 4656–4663.
Dong M, Phan AT , Yao JC . New strategies for advanced neuroendocrine tumors in the era of targeted therapy. Clin Cancer Res 2012; 18(7): 1830–1836.
Oberg KE . The management of neuroendocrine tumours: current and future medical therapy options. Clin Oncol (R Coll Radiol) 2012; 24(4): 282–293.
Lindholm DP, Oberg K. Biomarkers and molecular imaging in gastroenteropancreatic neuroendocrine tumors. Horm Metab Res 2011; 43(12): 832–837.
Turner GB, Johnston BT, McCance DR , et al. Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours. Gut 2006; 55(11): 1586–1591